CDK4 and breast cancer: These changes were coincident with increases in signaling by IFNγ, ILs, and STATs, as revealed by gene and protein expression profiles (Figure 3C; Table S2), and are consistent with studies in mammary tumor models showing that CDK4/6 inhibitors promote T cell-mediated tumor cell clearance by stimulating type III interferons and suppressing Treg cell proliferation.59